[{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2024-07-02T16:34:36.722Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2024-06-10"},{"id":"b5993f06-cb2c-4080-9676-30541427ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980460","created_at":"2021-01-18T03:49:34.064Z","updated_at":"2024-07-02T16:35:02.255Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT00980460","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • Torisel (temsirolimus) • vincristine • fluorouracil topical • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 236","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-21"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2024-07-02T16:35:08.377Z","phase":"Phase 2/3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-22"},{"id":"a20ca03c-e4c8-424b-9577-602d1900d998","acronym":"SWENOTECA-ABC","url":"https://clinicaltrials.gov/study/NCT02341989","created_at":"2021-01-18T11:07:54.417Z","updated_at":"2024-07-02T16:35:43.889Z","phase":"Phase 3","brief_title":"Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer","source_id_and_acronym":"NCT02341989 - SWENOTECA-ABC","lead_sponsor":"St. Olavs Hospital","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • etoposide IV • bleomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/01/2035","primary_completion_date":" 12/01/2035","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2023-07-06"},{"id":"09e15c9c-e287-4fad-a870-fd5bca457d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02423343","created_at":"2021-01-18T11:35:30.982Z","updated_at":"2024-07-02T16:36:24.656Z","phase":"Phase 1b/2","brief_title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT02423343","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR • ALK • AFP","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • AFP elevation","tags":["EGFR • ALK • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2021-09-09"},{"id":"e2f164db-cd6e-4810-b292-1a996805cfc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01049230","created_at":"2021-01-18T04:07:19.710Z","updated_at":"2024-07-02T16:36:36.619Z","phase":"Phase 2","brief_title":"Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors","source_id_and_acronym":"NCT01049230","lead_sponsor":"Massachusetts General Hospital","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-01-05"},{"id":"8a8f8f72-9d24-49f0-b8b8-cc3598e05ede","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075113","created_at":"2021-01-18T04:14:10.825Z","updated_at":"2024-07-02T16:36:56.758Z","phase":"Phase 1","brief_title":"Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer","source_id_and_acronym":"NCT01075113","lead_sponsor":"Virginia Commonwealth University","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 08/10/2010","start_date":" 08/10/2010","primary_txt":" Primary completion: 02/02/2017","primary_completion_date":" 02/02/2017","study_txt":" Completion: 07/18/2019","study_completion_date":" 07/18/2019","last_update_posted":"2019-08-20"},{"id":"d101eb1a-79fa-4466-a4c2-222ffa1769aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265692","created_at":"2021-01-18T10:38:53.849Z","updated_at":"2024-07-02T16:37:15.325Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT02265692","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • Torisel (temsirolimus) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 253","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-22"},{"id":"0de4063c-528c-47e5-8a5b-010691473205","acronym":"","url":"https://clinicaltrials.gov/study/NCT00039078","created_at":"2021-01-18T00:02:24.582Z","updated_at":"2024-07-02T16:37:20.678Z","phase":"Phase 2","brief_title":"Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00039078","lead_sponsor":"Allan Tsung","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraSphere (yttrium 90 microspheres)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 08/01/2000","primary_completion_date":" 08/01/2000","study_txt":" Completion: 08/01/2000","study_completion_date":" 08/01/2000","last_update_posted":"2017-06-26"},{"id":"04610283-47d7-4091-9c18-1ccd26727c12","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957905","created_at":"2021-01-18T03:43:42.428Z","updated_at":"2024-07-02T16:37:24.527Z","phase":"Phase 2","brief_title":"Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors","source_id_and_acronym":"NCT00957905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • oxaliplatin • leucovorin calcium • alvocidib (DSP-2033) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-03-10"},{"id":"3bbc8909-6663-4104-b1e4-35511534506d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03069508","created_at":"2021-01-18T15:07:18.115Z","updated_at":"2024-07-02T16:37:24.841Z","phase":"Phase 2a","brief_title":"Clemizole HCl for Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT03069508","lead_sponsor":"Eiger Group International, Inc.","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clemizole"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 02/13/2017","start_date":" 02/13/2017","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 01/31/2018","study_completion_date":" 01/31/2018","last_update_posted":"2017-03-03"},{"id":"0a4df933-f510-4bac-aee2-0275bbbb8549","acronym":"","url":"https://clinicaltrials.gov/study/NCT00453310","created_at":"2021-01-18T01:36:24.443Z","updated_at":"2024-07-02T16:37:36.411Z","phase":"Phase 2","brief_title":"Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment","source_id_and_acronym":"NCT00453310","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 11/01/2008","primary_completion_date":" 11/01/2008","study_txt":" Completion: 11/01/2008","study_completion_date":" 11/01/2008","last_update_posted":"2015-10-27"},{"id":"c64e89aa-a52e-43db-80fd-941320136f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00608361","created_at":"2021-03-25T14:48:47.352Z","updated_at":"2024-07-02T16:37:38.266Z","phase":"Phase 1","brief_title":"Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00608361","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2015-07-02"},{"id":"a72e6871-9ccf-486c-a1fd-7fb4980d4037","acronym":"","url":"https://clinicaltrials.gov/study/NCT00119314","created_at":"2021-01-18T00:24:08.414Z","updated_at":"2024-07-02T16:37:38.813Z","phase":"Phase 2","brief_title":"Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin","source_id_and_acronym":"NCT00119314","lead_sponsor":"University of Medicine and Dentistry of New Jersey","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • capecitabine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 07/01/2005","primary_completion_date":" 07/01/2005","study_txt":" Completion: 07/01/2005","study_completion_date":" 07/01/2005","last_update_posted":"2015-05-27"}]